Disease caused by the Ebola virus: from theory to practice
https://doi.org/10.22625/2072-6732-2015-7-1-5-17
Abstract
In the present paper summarizes the results of recent epidemiological, clinical, virological research aimed at studying the infection caused by the Ebola virus. Particular attention is paid to organizational measures to prevent the disease. Described principles of medical care to patients with Ebola hemorrhagic fever. Detailed part of the Medical Service of the Russian Federation Ministry of Defense in the establishment and organization of the martial infectious hospital with 100 beds in the Republic of Guinea.
About the Authors
K. V. Zhdanov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
I. V. Holikov
Main Military Medical Directorate, Moscow, Russia
Russian Federation
Russian Federation
References
1. Международные медико-санитарные правила (2005) / Второе издание. – Женева: ВОЗ, 2008. – 82 с. [cited 09.Jan.2015]. Available from: http://whqlibdoc.who.int/public atitions/2008/9789244580417_rus.pdf .
2. Editorial. Ebola: what lessons for the International Health Regulations? // The Lancet. – 2014. – Vol. 384,N 9951. – P. 1321.
3. Sanchez A. [et al.]. Filoviridae: Marburg and Ebola viruses. In: Knipe D.M., Howley P.M., eds. Fields virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins – 2006. – P. 1409-1448.
4. Geisbert T.W. Marburg and Ebola Hemorrhagic Fever (Filoviruses). In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Eighth Edition. – Philadelphia: Elsevier. – 2015. – P. 1995-1999.
5. Centers for Disease Control and Prevention. Bioterrorism agents/diseases. [cited 20 March 2010]. Available from: http:// www.bt.cdc.gov/agent/agentlist-category.asp#a.
6. Ebola haemorrhagic fever in Sudan, 1976. Report of an International Commission // Bull. of WHO. – 1978. – Vol. 56, N 2. – P. 247-270.
7. Ebola haemorrhagic fever in Zaire, 1976. Report of an International Commission. // Bull. of WHO. – 1978. – Vol. 56, N 2. – P.271-293.
8. Lefebvre A. Case fatality rates of Ebola virus diseases: A meta-analysis of World Health Organization data. / A. Lefebvre, C. Fiet, C. Belpois-Duchamp et al. // Médecine et maladies infectieuses. – 2014. – Vol. 44. – P. 412-416.
9. Платонов А.Е. Эбола, 2014 г. Эпидемиологические и социальные аспекты / А.Е. Платонов, О.В.Платонова, В.В. Малеев // Эпидемиология и инфекционные болезни. Актуальные вопросы. – 2014, No5. – С. 34-49.
10. WHO Ebola Response Team. Ebola Virus Disease in West Africa — The First 9 Months of the Epidemic and Forward Projections. N. Engl. J. Med., 2014; 371 (16): 1481-1495.
11. WHO: Ebola Response Roadmap Situation Report. [cited 07 Jan 2015]. Available from: http://apps.who.int/ebolaweb/sitreps/20150114/20150114.pdf.
12. Kuhn J.H. Proposal for a revised taxonomy of the family Filoviridae: Classification, names of taxa and viruses, and virus abbreviations / J.H. Kuhn, S. Becker, H. Ebihara et al. // Archives of Virology. – 2010. – Vol. 155, N 12. – P. 2083–2103.
13. Taylor D. Filoviruses are ancient and integrated into mammalian genomes / D. Taylor, R. Leach, J. Bruenn // BMC Evolutionary Biology, 2010. – Vol. 10. – P. 193.
14. Ebola and Marburg virus disease epidemics: preparedness, alert, control, and evaluation. INTERIM vers. 1.2. WHO., Geneva, Switzerland, 2014; 123 p. [cited 09 Jan 2015]. Available from: http://www.who.int/csr/disease/ebola/manual_EVD/ en/
15. Camacho A. Potential for large outbreaks of Ebola virus disease / A.Camacho, A.J. Kucharski, S. Funk et al. // Epidemics. – 2014. – Vol. 9. – P. 70-78.
16. Georges-Courbot M.C. Isolation and phylogenetic characterization of Ebola viruses causing different outbreaks in Gabon / M.C. Georges-Courbot, A. Sanchez, C.Y. Lu et al. // Emerg Infect Dis. – 1997. – Vol. 3, N1. – P. 59-62.
17. Leroy E.M. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007 / E.M. Leroy, A. Epelboin, V. Mondonge et al.// Vector Borne Zoonotic Dis. – 2009. – Vol. 9, N6. – P. 723-728.
18. MacIntyre C.R. Respiratory protection for healthcare workers treating Ebola virus disease (EVD): Are facemasks sufficient to meet occupational health and safety obligations? / C.R. MacIntyre, G.A. Richards, P.M. Davidson // International Journal of Nursing Studies. – 2014. – Vol. 51. – P. 1421–1426.
19. Personal Protective Equipment in the Context of Filovirus Disease Outbreak Response. Rapid advice guideline. October 2014. – WHO., Geneva, Switzerland, 2014; – 10 p. [cited 09 Jan 2015]. Available from: http://apps. who.int/iris/bitstream/ 10665/137410/1/WHO_EVD_Guidance_PPE_14.1_ eng.pdf )
20. World Health Organization (WHO), 2014b. Unprecedented Number of Medical Staff Infected with Ebola. [cited 09 Jan 2015]. Available from: http://www.who.int/ mediacentre/ news/ebola/25-august-2014/en
21. Gibbs N., edt. Person of the Year. The Choice. Time, 2014: Vol. 168 (26). [cited 05 Jan 2015]. Available from: http:// content.time.com/time/covers/0,16641,20061225,00.html.
22. Carette J.E. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1/ J.E. Carette, M. Raaben, A.C. Wong et al. // Nature. – 2011. – Vol. 477,N 7364. – P. 340– 343.
23. Kondratowicz A.S. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus / A.S. Kondratowicz, N.J. Lennemann, P.L. Sinn et al. // Proc. Natl. Acad. Sci. U.S.A. – 2011. – Vol. 108,N20. – P. 8426-8431.
24. Flemming A. Achilles heel of Ebola viral entry / A. Flemming // Nat. Rev. Drug. Discov. – 2011. – Vol. 10,N1. – P. 731-736.
25. Bray M. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus / M. Bray, S. Hatfill, L. Hensley et. al. // J Comp Pathol. – 2001. – Vol. 125. – P. 243-253.
26. Geisbert T.W. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection / T.W. Geisbert, L.E. Hensley, T. Larsen et al. // Am J Pathol. – 2003. – Vol. 163, N6. – P. 2347-2370.
27. Geisbert T.W. Pathogenesis of Ebola haemorrhagic fever in primate models: evidence that haemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells / T.W. Geisbert, H.A. Young, P.B. Jahrling et al. // Am J Pathol. – 2003. – Vol. 163,N6. – P. 2371-2382.
28. Mahanty S. Pathogenesis of filoviral haemorrhagic fevers / S. Mahanty, M. Bray // The Lancet Infectious Diseases. – 2004. – Vol. 4,N8. – P. 487-498.
29. Yang Z.Y. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury / Z.Y. Yang, H.J. Duckers, N.J. Sullivan et al. // Nat Med. – 2000. – 6,N8. – P. 886-889.
30. Zaki S.R., Goldsmith C.S. Pathologic features of filovirus infections in humans / S.R. Zaki, C.S. Goldsmith // Curr Top Microbiol Immunol. – 1999. – Vol. 235. – P. 97-116.
31. Sanchez A. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels / A. Sanchez, M. Lukwiya, D. Bausch et al. // J Virol. – 2004. – Vol. 78,N19. – P. 10370-10377.
32. Ebihara H. Molecular determinants of Ebola virus virulence in mice / H. Ebihara, A. Takada, D. Kobasa et al. // PLoS Pathog. – 2006. – 2,N7. – P. e73.
33. Feldmann H. Ebola haemorrhagic fever / H. Feldmann, T.W. Geisbert // Lancet. – 2011. – Vol. 377,N 9768. – P. 849862.
34. Bellan S.E. Ebola control: effect of asymptomatic infection and acquired immunity/ S.E. Bellan, J.R.C. Pulliam, J. Dushoff et. al. // Lancet. – 2014. – Vol. 384,N 9953. – P. 1499-1500.
35. Huggins J.W. Prospects for treatment of viral haemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug / J.W.Huggins // Rev Infect Dis. – 1989. – 11 (suppl 4) . – P. S750-S761.
36. Ignatyev G. Experimental study on the possibility of treatment of some haemorrhagic fevers / G. Ignatyev, A.Steinkasserer, M. Streltsova et. al. // J Biotechnol. – 2000. – Vol. 83. – P. 67-76.
37. Жданов К.В. Терапия геморрагической лихорадки Эбола / К.В. Жданов, А.В. Щеголев, А.Н. Коваленко // Воен.-мед. журн. – 2015. – Т. 336, No 3. – In press.
38. Ethical considerations for use of unregistered interventions for Ebola virus disease. Report of an advisory panel to WHO. (WHO/HIS/KER/GHE.14.1.) Geneva: World Health Organization, 2014. [cited 09 Jan 2015]. Available from: http:// who.int/csr/resources/publications/ebola/ethical-considerations/en/.
39. Potential Ebola therapies and vaccines. WHO/EVD/ HIS/EMP/14.1. – Geneva: World Health Organization, 5 November 2014. – 36 p.
40. Борисевич И.В.. Разработка и изучение свойств иммуноглобулина против лихорадки Эбола. / И.В. Борисевич, В.П. Краснянский, В.В. Михайлов и др. // Вопр. вирусол. 1995. Т. 40,No6. С. 194–197.
41. Dye J.M. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease / J.M. Dye, A.S. Herbert, A.I.Kuehne et. al. // Proc Natl Acad Sci USA. – 2012. – Vol. 109. – P.5034–5039.
42. Патент No 213038, Российская федерация RU 20.05.1999. Препарат, содержащий иммуноглобулин против лихорадки Эбола, из сыворотки крови лошадей, жидкий (Иммуноглобулин Эбола) / Михайлов В.В., Борисевич И.В., Тиманькова Г.Д., и др. Available from: http://www.vpk-news. ru/print.asp?pr_sign=archive.2004.33.articles.rostrum_01.
43. Smith L.M. Interferon-β Therapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg / L.M. Smith, L.E. Hensley, T.W. Geisbert et al. // Journal of Infectious Diseases. – 2013. – Vol. 208. – P. 310–318.
44. Qiu X. Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs / X. Qiu, G. Wong, L. Fernando et. al. // J. Virol. . – 2013. – Vol. 87,N13. – P. 7754 – 7757.
45. Qiu X. Successful treatment of Ebola virus–infected cynomolgus macaques with monoclonal antibodies / X. Qiu, J. Audet, G. Wong et al. // Sci. Transl. Med. – 2013. – Vol. 4,N 138. – P. 138ra81.
46. Pettitt J. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail / J. Pettitt, L. Zeitlin, H. Kim do et al. // Sci. Transl. Med. – 2013. – Vol. 5, N199. – P. 199ra113.
47. Mohammadi D. First trials for Ebola treatment announced / D. Mohammadi // The Lancet. – 2014. – Vol. 384, N 9957. – P. 1833.
48. O’Brien L.M. Vaccination with recombinant adenoviruses expressing Ebola virus glycoprotein elicits protection in the interferon alpha/beta receptor knock-out mouse / L.M. O’Brien, M.G. Stokes, S.G. Lonsdale et al. // Virology. – 2014. – Vol. 452, N 453. – P. 324–333.
49. Report of the Joint review meeting facilitated by the World Health Organization for the GSK ChAd3 Ebola Vaccine Clinical Trials Application / WHO, 15-16 December 2014. [cited 16 Dec 2014]. Available from: http://www.who.int/medicines/ ebola-treatment/meetings/gsk-vaccine-trials.pdf?ua=1.
50. WHO Ebola R&D Effort – vaccines, therapies, diagnostics [cited 30 Jan 2014]. Available from: http://www.who.int/ medicines/ebola-treatment/ebola_r_d_effort/en/.
51. В России разрабатывают три вакцины от лихорадки Эбола. [cited 11 Oct 2014]. Available from: http://www. newsru.com/russia/11oct2014/ebola.html.
52. Фисун А.Я. Болезнь, вызванная вирусом Эбола: клинико-диагностические аспекты и организация лечебнодиагностических мероприятий / А.Я. Фисун, К.В. Жданов, С.М. Захаренко и др. // Воен.-мед. Журн. – 2014. – Т. 335, No 11. – С. 4–11.
Review
For citations:
Zhdanov K.V., Holikov I.V. Disease caused by the Ebola virus: from theory to practice. Journal Infectology. 2015;7(1):5-17. (In Russ.) https://doi.org/10.22625/2072-6732-2015-7-1-5-17
Views:
1407
.png)
.png)
Email this article 